Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reconciling appropriations

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed President Pam Bailey will meet with Office of Management & Budget Director Josh Bolten July 28 to discuss the allocation of needed funds for the medical device user fee program. The program has received $1 mil. for the fiscal 2004 administration request and an additional $10 mil. through a Senate bill. According to the 1Senate Committee report, "the fiscal year 2004 budget request does not even come close to the second-year amount necessary to meet the requirements of the law." Under MDUFMA, the program would need to be given $30 mil. in FY 2005 to meet requirements. The Committee noted that it is "extremely disappointed by this lack of commitment to MDUFMA, and strongly encourages the FDA to include the necessary appropriation in the fiscal year 2005 budget request"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel